<DOC>
	<DOCNO>NCT00953329</DOCNO>
	<brief_summary>Study Status : Duke University Health System Institutional Review Board receive notification study termination ; final IRB closure date 12/12/2008 . Study enrollment close . Enrollment Update : Only one subject enter study expect enrollment 15 patient single site clinical trial . With recruitment interest , financial sponsor Sponsor-PI choose close clinical trial .</brief_summary>
	<brief_title>Alefacept Subjects With Chronic Plaque Psoriasis Who Failed Respond Anti-TNF Therapy</brief_title>
	<detailed_description>This open-label study use alefacept treatment patient chronic plaque psoriasis respond treatment anti-TNF agent . Patients respond Enbrel® 50 mg weekly 75 % reduction Psoriasis Area Severity Index ( PASI ) Score Physician Global Assessment ( PGA ) score 'almost clear ' 'clear ' , treat 15 mg alefacept intramuscularly ( IM ) weekly 20 week . Patients 'cleared ' 'almost clear ' end 12 week treatment alefacept complete 'standard treatment ' phase study . Study subject respond treatment initial 12 week continue alefacept therapy additional 8 weekly dos subject reach PGA 'almost clear ' 'clear ' . Alefacept FDA approve indication 12 week treatment clinical trial extend treatment window 8 additional week . Because increased exposure alefacept , subject carefully monitor treatment follow post-treatment 3 , 4 , 6 , 9 12 month last dose alefacept give . Purpose : This open-label study determine safety efficacy Amevive® 15 mg IM weekly subject chronic plaque psoriasis sufficiently respond etanercept , anti-TNF agent . The plan also determine length response time point relapse determine length time retreatment alefacept necessary . Patient Population : This study adult men woman , age 18 80 , chronic plaque psoriasis . At time enrollment , subject must receive 50 mg per week Enbrel without achieve response 'almost clear ' 'clear ' accord PGA respond 75 % reduction PASI Score .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Men woman age 18 80 year Subjects diagnose chronic plaque psoriasis require systemic therapy . Must receive antiTNF treatment without achieve response 'almost clear ' 'clear ' accord PGA respond 75 % reduction PASI score . Must willing receive 20 week IM injection weekly CD4 count must 250 cells/mm3 screen Diagnosis unstable erythroderma pustular psoriasis guttate psoriasis Serious local infection systemic infection 3 month prior receive study drug . Subjects CD4 lymphocyte count le 250 cells/mm3 study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>